Test Price
1,800 AEDโ Home Collection Available
Ethosuximide Therapeutic Drug Monitoring (TDM) Test โ Dubai
Executive Summary & Core Metrics
This quantitative immunoassay measures the serum trough concentration of ethosuximide, a first-line antiepileptic for absence seizures. Results are interpreted against the established therapeutic window of 40โ100 ยตg/mL to balance seizure control against haematological and neurological toxicity. The test is processed in an ISO 9001:2015 accredited laboratory and supported by temperature-controlled cold-chain logistics from sample collection through analysis.
- Accuracy Guarantee: 99.9 % diagnostic sensitivity via CE-IVD immunoassay cross-validated against LC-MS/MS.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection (daily 8 AM โ 11 PM).
- Clinical Guidance: Telephonic post-test interpretation and medication review with a qualified physician.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Ethosuximide is prescribed primarily for childhood absence epilepsy and juvenile myoclonic variants. Therapeutic monitoring requires a precisely timed trough specimen โ drawn immediately before the next oral dose โ to confirm that the serum concentration remains above the minimum effective threshold and below the level associated with bone marrow suppression, hepatotoxicity, or neurocognitive impairment. The laboratory employs a homogeneous immunoassay calibrated against international reference materials; all results are reviewed for haemolysis, lipaemia, and icterus interference before release.
| Feature | Our Test (DHA-Licensed Lab) | Closest Alternative |
|---|---|---|
| Methodology | Immunoassay (CE-IVD) validated against LC-MS/MS | Routine immunoassay without cross-validation |
| Turnaround Time | 2โ3 weeks (sample must be received by the 7th of the month) | 3โ5 weeks or sporadic send-out schedule |
| Pre-analytical Accuracy | Trough-optimised collection, cold-chain logistics, mandatory DHA Form 35 | No trough timing guidance, risk of SST tube interference |
| Price | 1,800 AED (inclusive of home collection fee) | 1,500โ2,200 AED |
Physician Insight & Safety Protocols
โIn my practice, a single ethosuximide level must always be correlated with the patientโs seizure diary, growth parameters (if paediatric), and a full blood count to rule out incipient marrow suppression. The 40โ100 ยตg/mL window is a guide, not a guarantee โ some patients achieve control at 35 ยตg/mL, while others tolerate 110 ยตg/mL without adverse effects. Always review the trough trend, not just one result.โ
โ Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132
โ ๏ธ Medication Advisory โ Do Not Self-Adjust
Never alter your ethosuximide dose or dosing interval without explicit instruction from the treating neurologist. Abrupt discontinuation can provoke status epilepticus. If you miss a dose, take it as soon as remembered unless the next scheduled dose is within 4 hours โ in that case, skip the missed dose entirely and resume the normal schedule. Double-dosing increases the risk of acute neurotoxicity.
Exclusion Criteria & Emergency Red Flags
- Do not present for phlebotomy during an acute seizure cluster โ call 998 for emergency medical care.
- Patients with a known hypersensitivity to medical-grade adhesives or latex must inform the phlebotomist before venepuncture.
- Postpone the test if you have a febrile illness (temperature >38 ยฐC) or an active infection; reschedule once clinically stable.
Patient FAQ & Clinical Guidance
1. Why must the blood sample be collected just before my next ethosuximide dose?
The trough concentration โ measured 10โ12 hours after the previous dose and immediately before the next one โ represents the lowest drug level during the dosing interval. This value confirms that your serum concentration never falls below the minimum effective threshold (40 ยตg/mL) and never rises above the toxic ceiling (100 ยตg/mL), ensuring round-the-clock seizure protection.
2. Can I use a serum separator tube (SST) for this test?
No. The gel barrier in SST tubes can adsorb the drug and interfere with the immunoassay reaction, producing falsely low results. Only a plain red-top tube (no additive, no gel) is acceptable. Please confirm with your phlebotomist that the correct tube is used before the draw.
3. What consent documentation is required before sample collection?
A fully completed Send-Out Consent Form (DHA Form 35) is mandatory. This authorises the laboratory to forward your specimen to the reference testing facility and confirms your acknowledgement of data handling under UAE privacy law. The form must be signed by the patient (or legal guardian for minors) and witnessed by the collecting clinician.
4. How long does it take to receive the result, and how will it be communicated?
The standard turnaround is 2โ3 weeks from the date the laboratory receives the specimen, provided the sample arrives by the 7th of the month. Results are delivered via secure email or the patient portal; a telephonic consultation with a physician is scheduled within 48 hours of result release to discuss clinical implications and any dose adjustments.
UAE Regulatory & Data Privacy Adherence
- Data Protection: All personal health information is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Consent: Patient consent and clinical governance follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Laboratory Credentials: DHA Facility License 1143 (Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE). Corporate brand: DNA Labs UAE. ISO 9001:2015 certified.
Clinical & Logistical Metadata
| Test Name | Ethosuximide Therapeutic Drug Monitoring (TDM) |
| Price (AED) | 1,800 AED (includes home collection fee) |
| Turnaround Time | 2โ3 weeks (sample must be received by the 7th of the month) |
| Sample Type / Matrix | Serum (plain red-top tube, no additive, no gel) |
| Methodology Used | Immunoassay (CE-IVD) cross-validated against LC-MS/MS |
| ICD-10-CM Code | Z51.81, G40.909 |
| LOINC Code | 3474-6 |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians